Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bausch Health Companies Inc
(TSX:
BHC
)
7.910
+0.080 (+1.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bausch Health Companies Inc
< Previous
1
2
3
Next >
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
August 13, 2024
Via
ACCESSWIRE
Bausch Health Announces Second Quarter 2024 Results
July 30, 2024
Via
ACCESSWIRE
Bausch Health Responds to Market Rumors
July 24, 2024
Via
ACCESSWIRE
Bausch Health Welcomes Two New Members to the Executive Leadership Team
July 19, 2024
Via
ACCESSWIRE
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
July 11, 2024
Via
ACCESSWIRE
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
June 20, 2024
Via
ACCESSWIRE
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
May 15, 2024
Via
ACCESSWIRE
Bausch Health Announces First Quarter 2024 Results
May 02, 2024
Via
ACCESSWIRE
Salix Announces 2024 Gastrointestinal Health Scholars Program
February 12, 2024
Via
ACCESSWIRE
CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
January 18, 2024
Via
ACCESSWIRE
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
June 14, 2024
Via
ACCESSWIRE
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
May 23, 2024
Via
ACCESSWIRE
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
May 17, 2024
Via
ACCESSWIRE
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
May 14, 2024
Via
ACCESSWIRE
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
May 09, 2024
Via
ACCESSWIRE
Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
January 18, 2024
Via
ACCESSWIRE
Bausch Health to Announce First-Quarter 2024 Results on May 2
April 11, 2024
Via
ACCESSWIRE
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
April 11, 2024
Via
ACCESSWIRE
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
April 11, 2024
Via
ACCESSWIRE
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
April 05, 2024
Via
ACCESSWIRE
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
April 03, 2024
Via
ACCESSWIRE
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
April 02, 2024
Via
ACCESSWIRE
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
March 06, 2024
Via
ACCESSWIRE
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
March 05, 2024
Via
ACCESSWIRE
Bausch Health Companies to Present at Cowen Annual Health Care Conference
March 01, 2024
Via
ACCESSWIRE
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
February 22, 2024
Via
ACCESSWIRE
Bausch Health Announces Board Refreshment
February 01, 2024
Via
ACCESSWIRE
Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
February 01, 2024
Via
ACCESSWIRE
CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
January 30, 2024
Via
ACCESSWIRE
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
January 07, 2024
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.